Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials

Mitchell, Paul; Korobelnik, Jean-François; Lanzetta, P; Holz, Frank G; Prunte, Christian; Schmidt-Erfurth, Ursula Margarethe; Tano, Yasuo; Wolf, Sebastian (2010). Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. British journal of ophthalmology, 94(1), pp. 2-13. London: BMJ Publishing Group 10.1136/bjo.2009.159160

[img] Text
3.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (690kB) | Request a copy

BACKGROUND: Neovascular age-related macular degeneration (AMD) has a poor prognosis if left untreated, frequently resulting in legal blindness. Ranibizumab is approved for treating neovascular AMD. However, further guidance is needed to assist ophthalmologists in clinical practice to optimise treatment outcomes. METHODS: An international retina expert panel assessed evidence available from prospective, multicentre studies evaluating different ranibizumab treatment schedules (ANCHOR, MARINA, PIER, SAILOR, SUSTAIN and EXCITE) and a literature search to generate evidence-based and consensus recommendations for treatment indication and assessment, retreatment and monitoring. RESULTS: Ranibizumab is indicated for choroidal neovascular lesions with active disease, the clinical parameters of which are outlined. Treatment initiation with three consecutive monthly injections, followed by continued monthly injections, has provided the best visual-acuity outcomes in pivotal clinical trials. If continued monthly injections are not feasible after initiation, a flexible strategy appears viable, with monthly monitoring of lesion activity recommended. Initiation regimens of fewer than three injections have not been assessed. Continuous careful monitoring with flexible retreatment may help avoid vision loss recurring. Standardised biomarkers need to be determined. CONCLUSION: Evidence-based guidelines will help to optimise treatment outcomes with ranibizumab in neovascular AMD.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Wolf, Sebastian

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0007-1161

ISBN:

19443462

Publisher:

BMJ Publishing Group

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:07

Last Modified:

30 Jun 2015 11:26

Publisher DOI:

10.1136/bjo.2009.159160

PubMed ID:

19443462

Web of Science ID:

000273650300002

BORIS DOI:

10.7892/boris.3

URI:

https://boris.unibe.ch/id/eprint/3 (FactScience: 126612)

Actions (login required)

Edit item Edit item
Provide Feedback